TROG 98.03 - Prostate - Margin +ve Post-Prostatectomy

By w.paterson
August 15, 2021
0 Comments

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Participating Centres

Current Accrual

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a

June 15, 2021

Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery

Ductal carcinoma in situ (DCIS) of the breast is

For over 30 years, TROG Cancer Research has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

TROG 98.04 – Liver Metastases

TROG 98.02/EFC3344 – Head & Neck/Tirapazamine (Phase II)

Related Post

Cancer trial participant hoping to help

Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery

TROG Cancer Research © 2022. All rights reserved

Website developed by the Marketing GP

TROG 98.03 – Prostate – Margin +ve Post-Prostatectomy

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

TROG 98.04 – Liver Metastases

TROG 98.02/EFC3344 – Head & Neck/Tirapazamine (Phase II)

Related Post

Cancer trial participant hoping to help

Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery